Global Human Immunodeficiency Virus (HIV) Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 100

Published Date: 12 Jan 2022

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Human Immunodeficiency Virus (HIV) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Human Immunodeficiency Virus (HIV) Therapeutics market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during review period. Hospitals accounting for  % of the Human Immunodeficiency Virus (HIV) Therapeutics global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While NRTIs segment is altered to a  % CAGR between 2022 and 2028.

Global key companies of Human Immunodeficiency Virus (HIV) Therapeutics include ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., and Bristol-Myers Squibb Company, etc. In terms of revenue, the global top four players hold a share over  % in 2021.

Market segmentation
Human Immunodeficiency Virus (HIV) Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    NRTIs
    NNRTIs
    Entry and Fusion Inhibitors
    Protease Inhibitors
    Integrase Inhibitors
    Coreceptor Antagonists

Market segment by Application, can be divided into
    Hospitals
    Clinics
    Labs

Market segment by players, this report covers
    ViiV Healthcare
    Mylan
    AbbVie
    Merck & Co., Inc.
    Bristol-Myers Squibb Company
    Boehringer Ingelheim GmbH
    Genentech, Inc.
    Cipla, Inc.
    Boehringer Ingelheim GmbH
    Genentech, Inc.

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Human Immunodeficiency Virus (HIV) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Human Immunodeficiency Virus (HIV) Therapeutics, with revenue, gross margin and global market share of Human Immunodeficiency Virus (HIV) Therapeutics from 2019 to 2022.
Chapter 3, the Human Immunodeficiency Virus (HIV) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Human Immunodeficiency Virus (HIV) Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Human Immunodeficiency Virus (HIV) Therapeutics research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Human Immunodeficiency Virus (HIV) Therapeutics
    1.2 Classification of Human Immunodeficiency Virus (HIV) Therapeutics by Type
        1.2.1 Overview: Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type in 2021
        1.2.3 NRTIs
        1.2.4 NNRTIs
        1.2.5 Entry and Fusion Inhibitors
        1.2.6 Protease Inhibitors
        1.2.7 Integrase Inhibitors
        1.2.8 Coreceptor Antagonists
    1.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Market by Application
        1.3.1 Overview: Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Labs
    1.4 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size & Forecast
    1.5 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast by Region
        1.5.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region, (2017-2022)
        1.5.3 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Prospect (2017-2028)
        1.5.4 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Prospect (2017-2028)
        1.5.6 South America Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers
        1.6.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints
        1.6.3 Human Immunodeficiency Virus (HIV) Therapeutics Trends Analysis

2 Company Profiles
    2.1 ViiV Healthcare
        2.1.1 ViiV Healthcare Details
        2.1.2 ViiV Healthcare Major Business
        2.1.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.1.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 ViiV Healthcare Recent Developments and Future Plans
    2.2 Mylan
        2.2.1 Mylan Details
        2.2.2 Mylan Major Business
        2.2.3 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.2.4 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Mylan Recent Developments and Future Plans
    2.3 AbbVie
        2.3.1 AbbVie Details
        2.3.2 AbbVie Major Business
        2.3.3 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.3.4 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 AbbVie Recent Developments and Future Plans
    2.4 Merck & Co., Inc.
        2.4.1 Merck & Co., Inc. Details
        2.4.2 Merck & Co., Inc. Major Business
        2.4.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.4.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Merck & Co., Inc. Recent Developments and Future Plans
    2.5 Bristol-Myers Squibb Company
        2.5.1 Bristol-Myers Squibb Company Details
        2.5.2 Bristol-Myers Squibb Company Major Business
        2.5.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.5.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
    2.6 Boehringer Ingelheim GmbH
        2.6.1 Boehringer Ingelheim GmbH Details
        2.6.2 Boehringer Ingelheim GmbH Major Business
        2.6.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.6.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
    2.7 Genentech, Inc.
        2.7.1 Genentech, Inc. Details
        2.7.2 Genentech, Inc. Major Business
        2.7.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.7.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Genentech, Inc. Recent Developments and Future Plans
    2.8 Cipla, Inc.
        2.8.1 Cipla, Inc. Details
        2.8.2 Cipla, Inc. Major Business
        2.8.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.8.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Cipla, Inc. Recent Developments and Future Plans
    2.9 Boehringer Ingelheim GmbH
        2.9.1 Boehringer Ingelheim GmbH Details
        2.9.2 Boehringer Ingelheim GmbH Major Business
        2.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
    2.10 Genentech, Inc.
        2.10.1 Genentech, Inc. Details
        2.10.2 Genentech, Inc. Major Business
        2.10.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
        2.10.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Genentech, Inc. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Human Immunodeficiency Virus (HIV) Therapeutics Players Market Share in 2021
        3.2.2 Top 10 Human Immunodeficiency Virus (HIV) Therapeutics Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Human Immunodeficiency Virus (HIV) Therapeutics Players Head Office, Products and Services Provided
    3.4 Human Immunodeficiency Virus (HIV) Therapeutics Mergers & Acquisitions
    3.5 Human Immunodeficiency Virus (HIV) Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Market Share by Type (2017-2022)
    4.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2017-2022)
    5.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2028)
    6.2 North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2028)
    6.3 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country
        6.3.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2028)
        6.3.2 United States Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        6.3.3 Canada Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        6.3.4 Mexico Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2028)
    7.2 Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2028)
    7.3 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country
        7.3.1 Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2028)
        7.3.2 Germany Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        7.3.3 France Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        7.3.5 Russia Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        7.3.6 Italy Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2028)
    8.2 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2028)
    8.3 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region
        8.3.1 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Region (2017-2028)
        8.3.2 China Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        8.3.3 Japan Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        8.3.4 South Korea Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        8.3.5 India Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        8.3.7 Australia Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2028)
    9.2 South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2028)
    9.3 South America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country
        9.3.1 South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2028)
        9.3.2 Brazil Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        9.3.3 Argentina Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2028)
    10.2 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2028)
    10.3 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country
        10.3.1 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2028)
        10.3.2 Turkey Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)
        10.3.4 UAE Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Human Immunodeficiency Virus (HIV) Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Region (2023-2028)
    Table 6. ViiV Healthcare Corporate Information, Head Office, and Major Competitors
    Table 7. ViiV Healthcare Major Business
    Table 8. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 9. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Mylan Corporate Information, Head Office, and Major Competitors
    Table 11. Mylan Major Business
    Table 12. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 13. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. AbbVie Corporate Information, Head Office, and Major Competitors
    Table 15. AbbVie Major Business
    Table 16. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 17. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors
    Table 19. Merck & Co., Inc. Major Business
    Table 20. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 21. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
    Table 23. Bristol-Myers Squibb Company Major Business
    Table 24. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 25. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
    Table 27. Boehringer Ingelheim GmbH Major Business
    Table 28. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 29. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Genentech, Inc. Corporate Information, Head Office, and Major Competitors
    Table 31. Genentech, Inc. Major Business
    Table 32. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 33. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Cipla, Inc. Corporate Information, Head Office, and Major Competitors
    Table 35. Cipla, Inc. Major Business
    Table 36. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 37. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
    Table 39. Boehringer Ingelheim GmbH Major Business
    Table 40. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 41. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Genentech, Inc. Corporate Information, Head Office, and Major Competitors
    Table 43. Genentech, Inc. Major Business
    Table 44. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product and Solutions
    Table 45. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 47. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 48. Breakdown of Human Immunodeficiency Virus (HIV) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 49. Human Immunodeficiency Virus (HIV) Therapeutics Players Head Office, Products and Services Provided
    Table 50. Human Immunodeficiency Virus (HIV) Therapeutics Mergers & Acquisitions in the Past Five Years
    Table 51. Human Immunodeficiency Virus (HIV) Therapeutics New Entrants and Expansion Plans
    Table 52. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) by Type (2017-2022)
    Table 53. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Type (2017-2022)
    Table 54. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Forecast by Type (2023-2028)
    Table 55. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022)
    Table 56. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Forecast by Application (2023-2028)
    Table 57. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 58. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 59. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 60. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 61. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 62. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 63. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 64. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 65. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 66. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 67. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 68. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 69. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 70. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 71. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 72. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 73. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Region (2017-2022) & (USD Million)
    Table 74. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Region (2023-2028) & (USD Million)
    Table 75. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 76. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 77. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 78. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 79. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 80. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2023-2028) & (USD Million)
    Table 81. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2017-2022) & (USD Million)
    Table 82. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2023-2028) & (USD Million)
    Table 83. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2017-2022) & (USD Million)
    Table 84. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2023-2028) & (USD Million)
    Table 85. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2017-2022) & (USD Million)
    Table 86. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Human Immunodeficiency Virus (HIV) Therapeutics Picture
    Figure 2. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type in 2021
    Figure 3. NRTIs
    Figure 4. NNRTIs
    Figure 5. Entry and Fusion Inhibitors
    Figure 6. Protease Inhibitors
    Figure 7. Integrase Inhibitors
    Figure 8. Coreceptor Antagonists
    Figure 9. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application in 2021
    Figure 10. Hospitals Picture
    Figure 11. Clinics Picture
    Figure 12. Labs Picture
    Figure 13. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 14. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
    Figure 15. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Region (2017-2028)
    Figure 16. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Region in 2021
    Figure 17. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 20. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 21. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 22. Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers
    Figure 23. Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints
    Figure 24. Human Immunodeficiency Virus (HIV) Therapeutics Market Trends
    Figure 25. ViiV Healthcare Recent Developments and Future Plans
    Figure 26. Mylan Recent Developments and Future Plans
    Figure 27. AbbVie Recent Developments and Future Plans
    Figure 28. Merck & Co., Inc. Recent Developments and Future Plans
    Figure 29. Bristol-Myers Squibb Company Recent Developments and Future Plans
    Figure 30. Boehringer Ingelheim GmbH Recent Developments and Future Plans
    Figure 31. Genentech, Inc. Recent Developments and Future Plans
    Figure 32. Cipla, Inc. Recent Developments and Future Plans
    Figure 33. Boehringer Ingelheim GmbH Recent Developments and Future Plans
    Figure 34. Genentech, Inc. Recent Developments and Future Plans
    Figure 35. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Players in 2021
    Figure 36. Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 37. Global Top 3 Players Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share in 2021
    Figure 38. Global Top 10 Players Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share in 2021
    Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 40. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Type in 2021
    Figure 41. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Share Forecast by Type (2023-2028)
    Figure 42. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Application in 2021
    Figure 43. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Share Forecast by Application (2023-2028)
    Figure 44. North America Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 45. North America Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 46. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 47. United States Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 48. Canada Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 49. Mexico Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 50. Europe Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 51. Europe Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 52. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 53. Germany Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 54. France Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 55. United Kingdom Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 56. Russia Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 57. Italy Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 59. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 60. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Region (2017-2028)
    Figure 61. China Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. Japan Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. South Korea Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 64. India Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 66. Australia Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 67. South America Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 68. South America Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 69. South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 70. Brazil Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 71. Argentina Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 72. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Type (2017-2028)
    Figure 73. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Sales Market Share by Application (2017-2028)
    Figure 74. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Country (2017-2028)
    Figure 75. Turkey Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 76. Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 77. UAE Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 78. Methodology
    Figure 79. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

ViiV Healthcare
Mylan
AbbVie
Merck & Co., Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Genentech, Inc.
Cipla, Inc.
Boehringer Ingelheim GmbH
Genentech, Inc.

Related Reports

Global Human Immunodeficiency Virus (HIV) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Global Human Immunodeficiency Virus (HIV) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

date 26 Feb 2021

date Pharma & Healthcare

The Human Immunodeficiency Virus (HIV) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Product Tags

human immunodeficiency virus hiv therapeutics

Human Immunodeficiency Virus (HIV) Therapeutics

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>